Abstract
Introduction
Ample evidence suggests that chronically elevated levels of nitric oxide (NO) are associated with protumorigenic [1, 2] and anti-apoptotic effects [3] . NO is produced from arginine by nitric oxide synthases (NOSs). Inducible NOS (iNOS or NOS2) generates high levels of NO and is capable of maintaining micromolar levels of NO for several days [4] . Expression and activity of iNOS is increased in various cancers including colorectal malignancies [5] [6] [7] [8] [9] . Increased iNOS activity means an increased demand for arginine. Sustained availability of high levels of arginine is required not only as the substrate for iNOS but also for enhanced synthesis of iNOS protein at the level of mRNA translation [10] . In addition, tumor growth requires enhanced protein synthesis, a process which would also depend on arginine availability. The mechanism by which this increased demand for arginine is met in malignant tissues remains unknown. Transport of arginine into mammalian cells is mediated by several amino acid transport systems, including y + , y + L, b 0,+ , ATA3 (also known as SNAT4) and B 0,+ [11] . Of these, only system B 0,+ is capable of mediating arginine entry into cells in a Na + /Cl À -coupled manner. Because of the three different driving forces (Na + gradient, Cl À gradient, and membrane potential) energizing ATB 0,+ , this transporter has the ability to concentrate arginine inside the cells several-fold higher than in the extracellular medium. Other transporters facilitate arginine entry into cells by a membrane potential-dependent mechanism alone (y + , y + L, b 0,+ ) and SNAT4 [11 -13] . The transporter responsible for system B 0,+ is known as ATB 0,+ (amino acid transporter B 0,+ ) [14, 15] . Previous studies of arginine delivery into cancer cells have focused on transporters other than ATB 0,+ [16] which are not highly concentrative. We hypothesized that the unique ability of ATB 0,+ to concentrate arginine inside the cells would make it an ideal mechanism for arginine delivery in cancer cells. To test this hypothesis, we compared the expression of ATB 0,+ mRNA and protein between paired normal and cancer tissues harvested from surgical specimens of patients with colorectal cancer. In each of the patients examined, the expression of ATB 0,+ is upregulated in colon cancer and in liver and lymph node metastases from colonic primaries.
Methods

Patients
This study received the Medical College of Georgia institutional review board's approval. Ten adult patients with colorectal adenocarcinoma, without polyposis or a history of prior chemoradiation, and two adult patients with hepatic metastasis from colonic primaries were included in this study after obtaining their informed consent. One of the patients with hepatic metastasis also had lymph node involvement.
Tissue collection and processing
A pathologist harvested normal colorectal epithelium and tissue from the luminal surface of the colorectal cancer from the freshly resected surgical specimens. Portions of the tissues (0.3 to 0.5 g from each site) from 11 patients were processed for total RNA extraction using TRIzol \ reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Tissues from each site were also fixed by immersion in neutral-buffered formalin for immunohistochemical studies. Tissue from the single patient with hepatic and lymph node metastasis was collected in neutral-buffered formalin for immunohistochemistry alone.
Semi-quantitative RT-PCR
Total RNA was denatured at 70 -C for 10 min and at 4 -C for 5 min in a GeneAmp PCR System 9700 thermocycler (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA) in the presence of oligo-dT and random hexamers (Promega Corporation, Madison, WI, USA). Reverse transcription was done using the Maloney murine leukemia virusreverse transcriptase (Promega) at 42 -C for 60 min, followed by 10 cycles of 65 -C for 50 s and 42 -C for 5 min. Incubating at 95 -C for 5 min inactivated the reverse transcriptase. The PCR primers for human ATB 0,+ and iNOS were designed based on published sequences (GenBank accession numbers: AF _ 151978 and NM _ 153292, respectively). The primers for ATB 0,+ were: 5V-GAAGGAGAAAGTGTCGGCTTCA-3V (sense) and 5V-TACCAC CTTGCCAGACGATTTG-3V (antisense). The expected size of the amplicon is 754 bp. These primers encompass a region within the sequence coding for the protein and therefore the expected RT-PCR product is likely to represent the long transcript (4.5 kb) as well as the short transcript (2 kb) of human ATB 0,+ [14] . The iNOS primers were: 5V-CTGGCCAGGGTG-GAAGCGGTAACA-3V (sense) and 5V-CACCACCAA-CAGCAGCCGTTCCTC-3V (antisense). The expected size of the amplicon is 1281 bp. The primers for SNAT4 were: 5V-CCAGATAGCTACATCGGGATA-3V (sense) and 5V-CAGGTAGAGGGCAGGGTATT-3V (antisense). These primers were based on the published sequence for human SNAT4 (GenBank accession no. NM _ 018018) [13] and the expected size of the amplicon is 688 bp. The PCR cycle number was determined such that the PCR amplification occurred within the linear range. As an internal control, 18S rRNA was amplified with a primer -competimer combination from QuantumRNAi Universal 18S rRNA Internal Standards Kit (Ambion Inc, Austin, TX, USA) according to the manufacturer's instructions for semi-quantitative RT-PCR. This kit supplies both 18S primers and competimers, the latter of which have been modified to block extension by DNA polymerase and thus reduce the efficiency of PCR amplification of the 18S cDNA. The optimum primer -competimer ratio was determined by serial dilutions such that 18S cDNA was amplified at a level similar to that of the target of interest. By thus equalizing the amplification efficiency of 18S and the target gene, multiplex PCR could be performed without competitive interference for primers limiting the quantification process. PCR with each pair of normal and cancer template cDNA was done using a cocktail of 18S rRNA primer -competimer (in the ratio 1:9), 10 Â PCR buffer with Mg 2+ , dNTP, forward and reverse primers, and TaKaRa Taq polymerase (Takara Bio Inc, Shiga, Otsu, Japan). Aliquots from the master mixture were added to cDNA from normal tissue and the corresponding cancer tissue. Negative controls were processed under identical conditions but without the addition of reverse transcriptase. The PCR protocol consisted of 3 min at 94 -C, followed by 30 cycles of denaturing at 94 -C for 60 s, annealing at 58 -C for 60 s for ATB 0,+ , and 62.5 -C for 60 s for iNOS, and extension at 72 -C for 60 s, followed by a single run of 72 -C for 10 min. The resultant multiplex PCR products (18S and either ATB 0,+ or iNOS) were run in agarose gels, stained with ethidium bromide and the intensities of the bands measured by densitometry using a SpectraImager 5000 Imaging system and AlphaEase 32-bit software (Alpha Innotech, San Leandro, CA, USA). The expression levels of ATB 0,+ and iNOS were normalized to the corresponding 18S rRNA, and the relative expression of the target genes in colon cancer compared to normal tissue from the same patient was determined. The RT-PCR products for ATB 0,+ and iNOS were sequenced to confirm their molecular identity. These RT-PCR products were then used as probes for Northern blot analysis.
Northern blot analysis
Total RNA was used to prepare poly(A) + RNA using oligo(dT)-microbeads (Miltenyi Biotec Inc, Auburn, CA, USA). 5 Ag of poly(A) + RNA from each specimen was then size-fractionated and transferred to Hybond N + nylon membrane (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer's instructions. The nylon membrane was pre-hybridized for 3 h at 42 -C with ULTRAhyb hybridization solution (Ambion Inc, Austin, TX, USA) and hybridized for 18 h with cDNA probes specific for human ATB 0,+ or iNOS. The cDNA probes were labeled by random priming using the Ready-to-go Oligo labeling beads (Amersham Biosciences) and a[
32 P]-dCTP (Amersham Biosciences). The membrane was washed twice at 60 -C for 30 min apiece in a low stringency buffer [2 Â salinesodium citrate (SSC), 0.5% w/v sodium dodecylsulfate (SDS)] and then twice in a high stringency buffer (0.2 Â SSC, 0.5% SDS). The membrane was exposed to Biomax-MS film (Eastman Kodak Company, Rochester, NY, USA) for 48 h (ATB 0,+ ) or 24 h (iNOS) at À80 -C. After quantifying the hybridization signal by densitometry, the membrane was stripped and re-probed with a 32 P-labeled cDNA probe specific for h-actin. The hybridization signals were expressed as a ratio of the target mRNA signal to the hactin mRNA signal. The ATB 0,+ -specific cDNA fragment resulting from the PCR represents a part of the region coding for the protein and this fragment overlaps with the probe used by Sloan and Mager [14] which detected two different splice variants of ATB 0,+ transcripts in human tissues.
Immunohistochemistry
Tissue samples obtained for immunohistochemistry were fixed in 10% neutral-buffered formalin and embedded in paraffin. Sections (5 Am) cut from the paraffin block were deparaffinized in xylene and rehydrated through graded alcohols. Normal and cancer tissue from the same patient was mounted on the same slide to ensure identical conditions. Endogenous peroxide activity was quenched with methanol/H 2 O 2 . Immunostaining was performed using a rabbit polyclonal anti-ATB 0,+ antibody [17] , mouse monoclonal anti-iNOS antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA), and rabbit polyclonal antinitrotyrosine antibody (Upstate Cell Signaling Solutions, Lake Placid, NY, USA). Immunohistochemistry was performed using the Labeled Streptavidin-Biotin 2 (LSAB2) detection system (DAKO Corp., Carpenteria, CA, USA). 3,3-Diaminobenzidine tetrahydrochloride was used as the chromogen. Negative controls unexposed to primary antibodies were processed in the same manner.
Statistical analysis
RT-PCR was repeated at least 4 times under identical conditions with each of the 11 pair of specimens. The log of the ratio of relative expression by RT-PCR and Northern blotting was analyzed using a linear mixed model that included subject and gel dates as random effects. Means and standard errors were calculated, and t-tests used as appropriate.
Results
Patient information
Ten adult patients with colorectal cancer, one patient (GM12) with a hepatic metastasis from a previously resected colon cancer, and one patient with liver and lymph node metastasis (GM38) were enrolled in the study (Table  1 ). There were 8 African-Americans and 4 Caucasians, 7 females and 5 males. The average age was 62 years (range 37 -82 years). Final pathology reports demonstrated that a range of poor, moderate and well-differentiated adenocarcinomas involving all areas of the colon were included in the study. All four stages of colorectal cancer, according to the TNM (Tumor, Node, Metastasis) classification developed by the American Joint Committee for Cancer/International Union Against Cancer, were present. The patient with a hepatic metastasis from a previously resected colonic primary (GM12) had the colonic resection done in another institute, and colonic tissue was not available to us. In this case, we harvested and compared normal and malignant hepatic tissue from the resected hepatic specimen. Histopathology confirmed normal hepatic tissue and hepatic metastasis from a primary mucinous colonic adenocarcinoma. The patient with lymph nodal and hepatic metastases (GM38) yielded specimens from the normal colon, the primary tumor as well as both the metastatic sites for immunohistochemistry alone.
Expression of ATB 0,+ and iNOS mRNA in normal and cancer tissue
Semi-quantitative RT-PCR for the analysis of mRNA levels for ATB 0,+ (Fig. 1A) and iNOS (Fig. 1B ) was performed and expression in normal colorectal epithelium and normal hepatic tissue was compared to that of tissue from the luminal surface of colorectal cancer or the metastasis, respectively, from the same patient. Normal colon and liver had minimal, but detectable, ATB 0,+ mRNA expression. The expression in cancer consistently showed a several-fold increase over the expression in the corresponding normal tissue in all 11 patients (colonic tissues from 10 patients and liver tissue from one patient). Overall, the 10 patients with colorectal cancer showed a 22.9 T 3.0-fold increase in ATB 0,+ mRNA expression over normal tissue (P < 0.0001). Hepatic metastasis from a colonic primary (GM12) showed a 28.6-fold increase in ATB 0,+ mRNA expression compared to normal hepatic tissue. The expression of iNOS mRNA in cancer consistently showed an increase over the expression in the corresponding normal tissue in all 11 patients. Overall, the 10 patients with colorectal cancer showed a 5.2 T 1.1-fold increase in the expression of iNOS mRNA over normal tissue (P < 0.002). Hepatic metastasis from a colonic primary (GM12) showed a 9.7-fold increase in iNOS mRNA expression compared to normal hepatic tissue.
Semi-quantitative RT-PCR results were confirmed by Northern blot analysis, using paired samples from three patients (Fig. 2) . As reported by Sloan and Mager [14] , ATB 0,+ had two different transcripts (2 kb and 4.5 kb in size) arising from alternative splicing. The steady-state levels of both transcripts increased in cancer. After normalization with h-actin mRNA levels, the larger transcript showed an increase of 19.8 T 5-fold in cancer compared to normal. The corresponding value for the shorter transcript was a 5.8 T 1.9-fold increase. Similarly, the semi-quantita- Fig. 1 . Semi-quantitative RT-PCR of paired normal and cancer tissue from colorectal cancer and metastasis. ATB 0,+ (A) and iNOS (B) mRNA expression was assessed by semi-quantitative RT-PCR in colorectal cancer and metastasis. Representative gels from normal (N) and cancer (C) tissue from each patient are shown in these composites. The patient's serial numbers (GM1, GM2, etc.) are given above the gels. The size of the ATB 0,+ -specific RT-PCR product is 754 bp and the size of the iNOS-specific RT-PCR product is 1281 bp. 18S rRNA is the internal control and the size of its specific RT-PCR product is 315 bp. The DNA size ladder is in the first lane of each composite. The mean ratio of mRNA expression in cancer tissue compared to normal tissue (Mean C/N ratio), after normalization with 18S rRNA levels, is shown below each pair. The lower limit of the 95% confidence interval (95% CI) is shown below the mean ratio for each patient's pair of samples. (C) Overall, colorectal cancer showed a 22.9 T 3.0-fold increase in ATB 0,+ mRNA expression ( P < 0.0001) and a 5.2 T 1.1-fold increase in iNOS mRNA expression ( P < 0.002) compared to patient-matched normal colorectal tissue. PCR was repeated with each RNA sample at least 4 times under identical conditions to obtain the cumulative data shown. N, Normal; C, Cancer. tive RT-PCR results for iNOS expression were also confirmed by Northern blot analysis. The increase in iNOS mRNA expression was 5.2 T 2-fold in cancer compared to normal.
There was no statistically significant correlation between the steady-state levels of ATB 0,+ mRNA and iNOS mRNA in cancer tissue or in normal tissue. There was no statistical correlation between the increases in the levels of ATB 0,+ mRNA and iNOS mRNA and the location, stage, or grade of the cancer or with the age, sex, or race of the patient.
Expression of SNAT4
SNAT4 is also a transporter for arginine and this transporter is energized by the membrane potential [12, 13] . Since SNAT4 has the ability to accumulate arginine inside the cells, we were interested to find out if the expression of this transporter is altered in colorectal cancer. We therefore compared the steady-state levels of SNAT4 mRNA in control and cancer samples by semi-quantitative RT-PCR (data not shown). With four different paired samples of colorectal cancer (GM1, GM2, GM6, and GM9) and one paired sample of liver metastasis (GM12), we found that the steady-state levels of SNAT4 mRNA did not change in three samples of colorectal cancer (GM1, GM6, and GM9) and that the levels increased in one sample (GM2). In the case of liver metastasis, the steady-state levels of SNAT4 mRNA decreased significantly in cancer compared to normal tissue. Thus, the changes in the expression levels of SNAT4 were not uniform in colorectal cancer.
Expression of ATB 0,+ protein
Representative immunohistochemical stains for ATB 0,+ protein in normal and cancer colon tissues from three patients are shown (Fig. 3) . Normal colonic epithelium from all three patients showed low, but detectable, expression of ATB 0,+ at the apical membrane and in the cytoplasm. The cancer tissue from the corresponding patients showed markedly elevated levels of ATB 0,+ protein, especially in the apical and basolateral membranes of the epithelial cells. Similarly, normal liver tissue far removed from the metastasis expressed very low levels of ATB 0,+ (Fig. 4A ), but the expression of the transporter protein was robust in the liver metastasis itself. The distribution pattern of ATB 0,+ in the liver metastasis was similar to that seen in the primary colon cancer with increased prominence in the apical membrane and in the basolateral membrane. The increased expression of ATB 0,+ protein was seen not only in the liver metastasis, but also in the immediately adjoining perimetastatic hepatic tissue that was microscopically free of cancer (Fig. 4B) . This metastasis-free, histologically normal, perimetastatic hepatic tissue expressed much higher levels of ATB 0,+ protein than normal hepatic tissue from a site far removed from the metastasis. The boundary of compressed tissue between the metastasis and the perimetastatic liver did not show expression of ATB 0,+ protein. Elevated levels of ATB 0,+ protein were also demonstrated in liver and lymph node metastases (Fig. 4C ) in another patient (GM38), and the distribution pattern of ATB 0,+ protein was similar to that seen in the primary cancer.
Expression of iNOS protein
Normal colonic epithelium from all patients expressed detectable levels of iNOS, staining with a diffuse, blush-like pattern. The cancer tissue from each subject showed increased, focally intense iNOS staining with an uneven distribution in the cytoplasm of the tumor cells. Representative immunohistochemical stains from one patient (GM1) are shown (Fig. 5A) . Normal liver showed very little iNOS protein expression (Fig. 5B) , but the hepatic metastasis demonstrated intense staining for iNOS protein with an intracellular distribution similar to the pattern seen in the primary cancer. In the cancer specimens as well as in the metastasis specimens, the sites of increased expression of iNOS protein were close to the apical and basolateral membranes of epithelial cells.
NO levels in cancer compared to normal tissue
Immunohistochemical analysis with an anti-nitrotyrosine antibody demonstrated increased staining in cancer tissue compared to normal in all patients. A representative immunostain from one patient (GM1) is shown (Fig. 6) . The nitrosylated tyrosine residues were present throughout the cytoplasm in a diffuse pattern in nearly all of the malignant epithelial cells.
Discussion
Colorectal cancer is the second most common cause of new cancer cases and cancer death in the United States [18] . Over-production of NO has been implicated in the pathogenesis of colorectal cancer [1] . Of the three NOS isoforms, over-activity of the iNOS isoform has been associated with colorectal cancer development. Kojima et al. [9] demonstrated a significant increase in iNOS mRNA expression in human colon cancer tissue compared to matched normal colonic epithelium from the same subjects. Immunohistochemical studies demonstrated that iNOS protein and nitrotyrosine residues were markedly increased in colon cancer, though it showed some variation from region to region in the cancer [19] . Our data confirm these previous findings with regard to increased expression of iNOS and increased levels of cellular proteins containing nitrotyrosine. Since NO is unstable, the levels of proteins containing nitrotyrosine represent a reliable indicator of in vivo exposure of the cellular proteins to NO and its metabolites. Our data also provide evidence for the increased expression of iNOS in liver metastasis from colonic primaries.
The most significant aspects of this study relate to the expression of the amino acid transporter ATB 0,+ . While there is convincing evidence in the literature for the increased demands for arginine in cancer tissues, very little information is available on the molecular mechanisms in colon cancer tissue that enable the tumor to meet these demands. Previous studies of arginine uptake were all done with colon cancer cell lines rather than native colon cancer tissue specimens. Cendan et al. [16] studied arginine transport before and after a mitogenic stimulus in SW480, a primary human colon adenocarcinoma cell line characterized by high levels of constitutive expression of iNOS and NO production. Arginine transport in unstimulated cells occurred via Na + -independent and Na + -dependent transport systems, the former contributing to a majority of total transport (70%). However, when stimulated with TGF-a and EGF, Na + -dependent arginine transport increased by 100% and 66%, respectively, while Na + -independent transport showed no change. Since a majority of arginine transport was mediated by Na + -independent systems even in stimulated cells, the emphasis of the study was not directed to the Na + -dependent arginine transport systems. In a follow-up study, these investigators used the SW620 cells, a metastatic NO producing colon cancer cell line derived from the same patient that provided the SW480 cell line [20] . When the transport of arginine via Na + -independent and Na + -dependent processes was compared between the two cell lines, the authors noted that transport via Na + -independent systems was much higher in the more proliferative, metastatic SW620 cells than in the primary colon cancer cell line SW480. Based on these findings, the authors concluded that Na + -independent transport systems are more relevant than Na + -dependent transport systems for the delivery of arginine into colon cancer cells.
In the present study, we focused on the Na + /Cl À -dependent amino acid transport system ATB 0,+ and used paired native normal colon and colorectal cancer tissue specimens instead of colon cancer cell lines. ATB 0,+ is expressed in the brush border of normal colonocytes [21] . The transport of arginine via ATB 0,+ is coupled to transmembrane gradients of Na + and Cl À and to membrane potential. Studies in our laboratory have shown that the Na + /Cl À / amino acid stoichiometry is 2:1:1 irrespective of whether the transported amino acid is a neutral amino acid or a cationic amino acid (Hatanaka et al, unpublished data) . With this stoichiometry, transport of a zwitterionic neutral amino acid such as glycine will be associated with the transfer of a single positive charge into cells per cycle, whereas the transport of a cationic amino acid such as arginine will be associated with the transfer of two positive charges into the cell per cycle. This increases the contribution of the membrane potential as a driving force for the cellular uptake of cationic amino acids and thus enhances the concentrative ability of ATB 0,+ for arginine compared to neutral amino acids. Thus, ATB 0,+ with its unique ability to mediate the influx of arginine into cells may be ideally suited to meet the increased demands for arginine in cancer cells.
The present studies have shown unequivocally that, in each and every colorectal cancer specimen examined, the expression of ATB 0,+ is increased several-fold compared to corresponding control specimens from the same patients. The increase in expression is about 20-fold in terms of steady-state levels of ATB 0,+ mRNA. The increase in mRNA levels is accompanied by a parallel increase in ATB 0,+ protein in every colorectal cancer specimen. These findings are remarkable for their consistency and reproducibility in all of the patients in the study. The data from liver and lymph node metastases are also compelling. The increased expression of ATB 0,+ protein is clearly evident in the metastases. The detection of enhanced ATB 0,+ in the histologically normal perimetastatic region of the liver tissue suggests that cancer cells may elaborate certain factors that might act on the adjacent liver cells to induce the expression of the transporter.
SNAT4 is a transporter that has the ability to accumulate arginine inside the cells by a process energized by the membrane potential [13] . This transporter is, however, expressed normally only in liver [12, 13] . There is no information available in the literature on cancer-associated alterations in the expression of this transporter in tumor tissues. In the present study, we investigated the expression of SNAT4 in control and paired cancer tissues from patients with colorectal cancer. In a majority of cases, the expression of this transporter was not altered in association with cancer. There was, however, one case in which the expression was increased in cancer tissue compared to the corresponding cancer tissue. Since this transporter is expressed predominantly in the liver under normal conditions, we examined the expression of the transporter in liver metastasis of colon cancer. We found the expression to be decreased in liver metastatic tissue compared to the control liver tissue. Thus, the cancer-associated changes in the expression of SNAT4 were not uniform in all cancer samples.
Extracellular arginine supports NO production in a variety of cell types. However, intracellular concentrations of arginine are around 100 AM and all three isoforms of NOS have a K m for arginine in the range of 3 -30 AM [22] . NOS should be saturated with arginine and function at maximal levels at these concentrations. Therefore, extracellular arginine should have no effect on NO production via NOS. However, exposure of the cells to extracellular arginine does lead to increased production of NO. These apparently contradicting findings, originally observed in eNOS-expressing endothelial cells, are known as the ''arginine paradox'' [23] . It is believed that compartmentalization of eNOS and cytosolic arginine limits eNOS's access to cytosolic arginine in endothelial cells. Co-localization of eNOS with the Na + -independent arginine transporter CAT-1 (one of the three isoforms of arginine transporters responsible for system y + transport activity) is believed to underlie the observation that extracellular arginine increases NO production via eNOS [24] . The levels of NO generated by eNOS are several orders of magnitude lower than those generated by iNOS. Therefore, NO production via iNOS could be expected to depend on extracellular arginine to a greater extent than that seen with eNOS. CAT-1 with its limited ability to concentrate arginine in cells is not suited to meet the demands for arginine in cancer cells over-expressing iNOS. ATB 0,+ is likely to be the transporter that is responsible for delivering arginine to iNOS for production of NO in cancer cells. The striking colocalization of ATB 0,+ and iNOS in cancer specimens observed in the present study underscores the potential functional relationship between the arginine delivery process (ATB 0,+ ) and NO synthesizing machinery (iNOS). Arginine is also an essential amino acid for cancer cells to sustain cancer cell growth [25] . It is likely that cancer cells upregulate the expression of ATB 0,+ to obtain this amino acid from the extracellular medium to support growth as well as excess NO production. The present studies have shown convincingly that the expression of ATB 0,+ is upregulated in colorectal cancer, both at the mRNA level and at the protein level. We hypothesize that this upregulation is accompanied with a parallel increase in transport function, enhancing the delivery of extracellular arginine into cancer cells. Additional studies are needed however to confirm this hypothesis.
The upregulation of ATB 0,+ in cancer makes this transporter a potential tool for the delivery of chemotherapeutic agents. We have shown previously that ATB 0,+ is a versatile delivery system for a variety of drugs and prodrugs [26, 27] . ATB 0,+ is also highly suitable for the delivery of NOS inhibitors into cells [28] . This class of compounds may have use in cancer chemotherapy [29] . NOS inhibitors are substrates for ATB 0,+ and therefore instead of arginine entering the cancer cells via this transporter, NOS inhibitors would gain access into cells. Once inside the cells, NOS inhibitors block the function of iNOS and suppress the generation of NO. As the expression of ATB 0,+ is markedly and specifically elevated in cancer cells, the actions of NOS inhibitors can be expected to be directed primarily to cancer cells. These data may also be relevant to the treatment of patients with lymphatic spread or hepatic metastasis from colonic primaries. Normal lymph nodes and liver express very little ATB 0,+ [14] , but the expression of the transporter is markedly enhanced in colorectal cancer metastases in the lymph nodes and liver. Perimetastatic regions of the liver, free of metastasis, also express high levels of ATB 0,+ thus ensuring a Fkill zone_ around the metastasis where chemotherapeutic agents could be delivered in a manner similar to establishing negative margins after surgical resection. Using this transporter for pharmacotherapy may therefore be beneficial in patients with colon cancer with and without lymphatic spread and hepatic metastasis.
